| Literature DB >> 30830561 |
Siew-Li Goh1,2, Monica S M Persson1, Joanne Stocks1, Yunfei Hou3, Nicky J Welton4, Jianhao Lin3, Michelle C Hall5, Michael Doherty1, Weiya Zhang6.
Abstract
BACKGROUND: Guidelines recommend exercise as a core treatment for osteoarthritis (OA). However, it is unclear which type of exercise is most effective, leading to inconsistency between different recommendations.Entities:
Mesh:
Year: 2019 PMID: 30830561 PMCID: PMC6459784 DOI: 10.1007/s40279-019-01082-0
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Study flow diagram for comparison between exercise and usual care and between different exercises. NMA network meta-analysis, RCT randomised controlled trials
Characteristics of included studies
| Study | Age (SD) | BMI (SD) | Jt | Diagnosis | Pre-surgical | Study arms | Tool and outcome time point (month) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Pain | Function | Performance | QoL | |||||||
| Abbott et al. [ | 67 (10) | 29 (6) | 206 (55) | K, H | A | N | MEx | UC | – | Pain intensity score (0–10), 12 | WOMAC (0–240), 2.25 | 40-m walk time (s), 12 | – |
| Aglamis et al. [ | 56 (5) | 33 (5) | 31 (100) | K | A, I | N | MEx | UC | – | VAS (0–10), 1.5 | WOMAC (total), 1.5 | 6MWT (m), 1.5 | SF-36 (0–100) general health (0–100), 1.5 |
| An et al. [ | 65 (7) | 26 (3) | 28 (100) | K | A | N | MB | UC | – | WOMAC pain, 2 | WOMAC (physical fx), 2 | 6MWT (m), 2 | SF-36 mental health (0–100), 2 |
| Aoki et al. [ | 73 (6) | 26 (3) | 36 (100) | K | I | Y | Fl/Sk | UC | – | VAS (0–100), 3 | – | Walking speed (m/min), 3 | – |
| Arnold and Faulkner [ | 74 (6) | 30 (5) | 83 (68) | H | A | N | MEx | UC | – | Arthritis Impact measurement scale –2, results not reported | Activity specific balance confidence (0–100), 2.75 | 6MWT (m), 2.75 | – |
| Beaupre et al. [ | 67 (7) | 32 (6) | 131 (55) | K | UClr | Y | Str | UC | – | WOMAC pain (0–100), 1.5 | WOMAC fx (0–100), 1.5 | Quadriceps strength, 1.5 | SF-36 mental health, 1.5 |
| Bennell et al. [ | 65 (8) | 28 (4) | 89 (48) | K | A, I | N | Str | UC | – | NRS (0–10), 3.25 | WOMAC fx (0–68), 3.25 | Timed stair task (s), 3.25 | – |
| Bennell et al. [ | 62 (7) | 30 (4) | 100 (52) | K | I | N | Fl/Sk | Str | – | VAS (0–100), 3 | WOMAC fx (0–68), 3 | Walking speed (m/s), 3 | AQoL (− 0.04–1), 3 |
| Bieler et al. [ | 70 (–) | 27 (–) | 152 (68) | H | A | N | Ae | MEx | Str | WOMAC pain, not extractable | WOMAC fx, not extractable | 6MWT (m), 2 | SF-36, not extractable |
| Börjesson et al. [ | 64 (5) | – (–) | 68 (50) | K | I | Y | MEx | UC | – | NRS (0–10), 3 | – | Walking speed (m/s), 3 | – |
| Braghin et al. [ | 60 (–) | 31 (–) | 42 (74) | K | I | N | MEx | UC | – | WOMAC pain, 2 | WOMAC fx, 2 | Timed movement (s), 2 | – |
| Bruce-Brand et al. [ | 64 (5) | 33 (4) | 26 (42) | K | I | Y | Str | UC | – | WOMAC pain (0–20), 1.5 | WOMAC fx, 1.5 | Timed walk (s), 1.5 | SF-36 MCS, 1.5 |
| Calatayud et al. [ | 50 (–) | 32 (–) | 50 (–) | K | A, I | Y | Str | UC | – | VAS (0–10), 2 | WOMAC fx, 2 | Timed up and go (s), 2 | SF-36 physical fx, 2 |
| Chaipinyo and Karoonsupcharoen [ | 66 (7) | 25 (4) | 48 (77) | K | A | N | Fl/Sk | Str | – | KOOS pain (0–100), 1 | KOOS fx daily activity (0–100), 1 | Timed walk (s), 1 | KOOS QoL (0–100), 1 |
| Chen et al. [ | 63 (7) | – (–) | 120 (85) | K | A, I | N | Str | UC | – | VAS (0–10), 2 | Lequesne’s index (1–26), 2 | Knee range of motion, 2 | – |
| Cheung et al. [ | 72 (8) | 29 (7) | 83 (84) | K | A | N | MB | MEx | – | VAS (0–10), 2 | WOMAC fx (0–68), 2 | Walking 50 ft (s), 2 | SF-12 MCS, 2 |
| Chopp-Hurley et al. [ | 54 (–) | 29 (–) | 24 (79) | K, H | A | N | Str | UC | – | ICOAP, not extractable | HOOS/KOOS, not extractable | 6MWT (m), 3 | HOOS/KOOS, not extractable |
| Christensen et al. [ | 63 (6) | 37 (–) | 192 (81) | K | I | N | MEx | UC | – | VAS (0–100), 12 | KOOS (daily fx) (0–100), 12 | 6MWT (m), 12 | SF-36 mental health (0–100), 12 |
| Cochrane et al. [ | 70 (7) | 30 (–) | 312 (63) | K, H | UClr | N | MEx | UC | – | WOMAC pain (0–96), 6 | WOMAC fx (0–96), 6 | Timed walk (s), 12 | SF-36 mental health (0–100), 6 |
| Cheung et al. [ | 72 (6) | 29 (–) | 36 (100) | K | A | N | MB | UC | – | WOMAC pain (0–20), 2 | WOMAC fx (0–68), 2 | 8-min walk (m), 2 | SF-12 MCS (0–100), 2 |
| D’Lima et al. [ | 70 (6) | – (–) | 30 (47) | K | UClr | Y | Ae | Mex | UC | – | Hospital for Special Surgery Knee rating (0–100), 1.5 | – | – |
| Duracoglu et al. [ | – (–) | – (–) | 66 (100) | K | A, I | N | MEx | Str | – | – | WOMAC fx, 2 | Timed walk (s), 2 | SF-36 vitality, 2 |
| Ebnezar et al. [ | 60 (10) | – (–) | 250 (70) | K | A, I | N | MB | MEx | – | NRS (0–10), 3-month | WOMAC (0–96), 3 | – | – |
| Espejo Antunez et al. [ | 84 (8) | – (–) | 31 (77) | K | A | N | MEx | UC | – | VAS, 1-month | WOMAC fx (0–96), 1 | – | SF-36 mental health, 1 |
| Ettinger et al. [ | 69 (6) | – (–) | 439 (70) | K | I | N | Ae | Str | – | Likert scale (1–6), 3 | Self-reported physical disability (1–5), 3 | 6MWT (m), 3 | – |
| Evcik and Sonel [ | 56 (6) | – (–) | 90 (62) | K | I | N | Ae | UC | – | VAS (0–100), 6 | WOMAC fx (0–68), 6 | – | NHP—emotional reaction, 6, outlier |
| Evgeniadis et al. [ | 68 (4) | 34 (–) | 53 (79) | K | A, I | Y | Str | UC | – | SF-36 body pain, 1 | SF-36 physical fx, 1 | Active range of motion (flexion), 1 | SF-36 mental health, 1 |
| Ferrara et al. [ | 63 (8) | – (–) | 23 (61) | H | UClr | Y | MEx | UC | – | VAS (0–10), 1 | WOMAC fx (0–68), 1 | Quads strength, 1 | SF-36 mental health, 1 |
| Fitzgerald et al. [ | 64 (9) | 30 (–) | 183 (67) | K | A, I | N | Fl/Sk | MEx | – | NRS (0–10), 2 | WOMAC fx (0–68), 2 | Up and go (s), 2 | Global rating of change, 2 |
| Fransen et al. [ | 67 (9) | 29 (5) | 126 (73) | K | I | N | MEx | UC | – | WOMAC pain (0–100), 2 | WOMAC fx (0–100), 2 | Gait speed (cm/s), 2 | SF-36 mental health, 2 |
| Fransen et al. [ | 70 (6) | 30 (–) | 152 (74) | K, H | A | N | MB | MEx | UC | WOMAC pain (0–100), 3 | WOMAC fx (0–100), 3 | Timed walk (s), 3 | SF-12 MCS (mean ± SD 50 ± 10), 3 |
| French et al. [ | 62 (10) | – (–) | 131 (64) | H | A, I | N | MEx | UC | – | NRS, 2 | WOMAC fx (0–68), 2 | 50-ft walk test (s), 2 | SF-36 mental health (0–100), 2 |
| Ghroubi et al. [ | 41 (10) | 38 (–) | 56 (–) | K | I | N | MEx | UC | – | VAS pain (0–10), 2 | WOMAC, 2 | 6MWT (m), 2 | – |
| Gomiero et al. [ | 62 (–) | 24 (–) | 64 (95) | K | A | N | Fl/Sk | Str | – | VAS (0–100), 4 | WOMAC (total), 4 | Timed up and go (s), 4 | SF-36 mental health, 4 |
| Gondhalekar and Deo [ | 63 (6) | – (–) | 30 (50) | K | A, I | N | Fl/Sk | Str | – | VAS (0–10), 0.75 | WOMAC, 0.75 | Hip extensor strength, 0.75 | – |
| Gur et al. [ | 56 (12) | – (–) | 23 (–) | K | I | N | Str | UC | – | NRS (0–10), 2 | NRS of functional capacity (0–10), 2 | 15-m walk (s), 2 | – |
| Hasegawa et al. [ | 77 (4) | 24 (4) | 28 (64) | K | UClr | N | MEx | UC | – | NRS (0–10), 3 | – | Time up and go (s), 3 | – |
| Henriksen et al. [ | 64 (8) | 29 (–) | 60 (80) | K | I | N | MEx | UC | – | KOOS pain (0–100), 3 | KOOS fx (0–100), 3 | Walking speed (m/s), 3 | KOOS QoL (0–100), 3 |
| Hermann et al. [ | 70 (8) | 28 (5) | 80 (65) | H | UClr | Y | Str | UC | – | HOOS pain, 2.5 | HOOS ADL, 2.5 | Quadriceps power, 2.5 | HOOS QoL, 2.5 |
| Hinman et al. [ | 62 (9) | 33 (7) | 71 (68) | K, H | A, I | N | MEx | UC | – | VAS (0–10) on movement, 1.5 | WOMAC fx (0–1700), 1.5 | 6MWT (m), 1.5 | Assessment of QoL (− 0.04 to 1), 1.5 |
| Hiyama et al. [ | 73 (5) | 24 (–) | 40 (100) | K | UClr | N | Ae | MEx | – | Japanese Knee Osteoarthritis Measure pain (0–125), 1 | Japanese Knee Osteoarthritis Measure (total) (0–125), 1 | Timed up and go (s), 1 | – |
| Hoogeboom et al. [ | 76 (4) | 27 (–) | 21 (67) | H | UClr | Y | MEx | UC | – | VAS, 1 | HOOS ADL fx (0–100), 1 | 6MWT (m), 1 | HOOS QoL (0–100), 1 |
| Huang et al. [ | 62 (5) | – (–) | 132 (71) | K | A, I | N | MEx | UC | – | VAS (0–10), 2 | Lequesne index, 2 | Walking speed (m/s), 2 | – |
| Huang et al. [ | 65 (6) | – (–) | 140 (81) | K | A | N | Str | UC | – | VAS (standing/walking) (0–10), 2 | Lequesne index (1–26), 2 | Walking speed (m/min), 2 | – |
| Huang et al. [ | 68 (6) | 25 (2) | 250 (80) | K | A | N | Str | UC | – | VAS (0–100), 3 | WOMAC (0–68), 3 | – | – |
| Hunt et al. [ | 66 (11) | 27 (–) | 17 (53) | K | A, I | N | Str | UC | – | – | – | Walking speed (m/s), 2.5 | – |
| Ikuta et al. [ | 72 (6) | – (–) | 27 (100) | K | UClr | N | Fl/Sk | MEx | – | KOOS pain, 1 | KOOS ADL, 1 | Walking speed (km/h), 1 | SF-36 mental health, 1 |
| Jan et al. [ | 63 (7) | – (–) | 98 (81) | K | A, I | N | Str | UC | – | WOMAC pain (0–20), 2 | WOMAC fx (0–68), 2 | Timed walk (s), 2 | – |
| Jan et al. [ | 63 (7) | – (–) | 106 (69) | K | A, I | N | Str | UC | – | – | WOMAC fx (0–68), 2 | Timed walk (s), 2 | – |
| Jorge et al. [ | 61 (7) | 31 (4) | 60 (100) | K | A | N | Str | UC | – | VAS (0–10), 1.5 | WOMAC (0–68), 1.5 | 6MWT (m), 1.5 | SF-36 mental health (0–100), 1.5 |
| Juhakoski et al. [ | 67 (6) | – (–) | 118 (70) | H | A, I | N | MEx | UC | – | WOMAC pain (0–100), 3 | WOMAC fx (0–100), 3 | 6MWT (m), 3 | SF-36, not reported |
| Koli et al. [ | 59 (4) | 27 (4) | 78 (100) | K | I | N | Ae | UC | – | KOOS pain (0–100), 12 | KOOS fx (0–100), 12 | Strength, 12 | KOOS QOL (0–100), 12 |
| Krasilshchikov et al. [ | 58 (5) | 28 (5) | 16 (100) | K | I | N | MEx | UC | – | WOMAC pain, 2 | WOMAC fx, 2 | 6MWT (m), 2 | – |
| Krauss et al. [ | 59 (10) | 27 (4) | 218 (40) | H | A | N | MEx | UC | – | WOMAC pain (0–100), 3 | WOMAC fx (0–100), 3 | Hip and peak torque, 3 | SF-36 mental health (0–100), 3 |
| Kreindler et al. [ | – (–) | – (–) | 32 (75) | K | UClr | N | Str | UC | – | – | – | Quadriceps strength (180), 1.5 | – |
| Kumar et al. [ | 53 (6) | 25 (3) | 44 (57) | K | UClr | N | Fl/Sk | Str | – | NRS, 1 | WOMAC fx, 1 | Joint position sense error, 1 | – |
| Lee and Lee [ | 76 (6) | – (–) | 46 (78) | K | UClr | N | MB | UC | – | WOMAC pain (0–96), 3 | WOMAC fx (0–96), 3 | Timed up and go test (s), 3 | – |
| Lee et al. [ | 69 (5) | – (–) | 44 (93) | K | I | N | MB | UC | – | WOMAC pain (26–130), 2 | WOMAC fx (0–100), 2 | 6MWT (m), 2 | SF-36 mental health (0–100), 2 |
| Lim et al. [ | 66 (8) | 29 (–) | 107 (55) | K | A, I | N | Str | UC | – | WOMAC pain (0–100), 3 | WOMAC fx (0–100), 3 | Stair climb (s), 3 | – |
| Lin et al. [ | 62 (7) | – (–) | 89 (70) | K | I | N | Fl/Sk | Str | – | – | WOMAC fx (0–69), data not extractable | Knee extensor torque (180o), 2 | – |
| Lin et al. [ | 63 (7) | – (–) | 108 (69) | K | I | N | Fl/Sk | Str | UC | WOMAC pain (0–20), 2 | WOMAC fx (0–68), 2 | Timed walk (s), 2 | – |
| Lund et al. [ | 68 (14) | – (–) | 79 (79) | K | A | N | MEx | UC | – | VAS at rest (0–100), 2 | KOOS ADL (0–100), 2 | Strength, 2 | – |
| Messier et al. [ | 69 (6) | 31 (6) | 103 (74) | K | I | N | Ae | Str | – | Pain intensity (1–6), 3 | – | – | – |
| Moghadam and Shojaedin [ | 67 (–) | 25 (–) | 20 (–) | K | A | N | Ae | UC | – | – | – | 6MWT (m), 2 | – |
| Munukka et al. [ | 64 (–) | 27 (–) | 87 (100) | K | I | N | Str | UC | – | KOOS pain (0–100), 4 | KOOS ADL (0–100), 4 | Walking speed (m/s), 4 | KOOS QoL (0–100), 4 |
| Oida et al. [ | 74 (5) | 25 (4) | 88 (86) | K | I | N | MEx | UC | – | – | WOMAC (0–300), 3 | Timed walk (s), 3 | – |
| Oosting et al. [ | 76 (6) | 28 (–) | 30 (80) | H | UClr | Y | MEx | UC | – | NRS (0–10), 1.25 | HOOS ADL fx (0–100), 1.25 | 6MWT (m), 1.25 | HOOS QoL (0–100), 1.25 |
| O’Reilly et al. [ | 62 (10) | – (–) | 180 (66) | K | UClr | N | Str | UC | – | WOMAC pain (0–20), 6 | WOMAC fx (0–68), 6 | Quadriceps strength, 6 | SF-36 mental health, 6 |
| Petrella and Bartha [ | 74 (5) | – (–) | 179 (58) | K | I | N | Fl/Sk | MEx | – | WOMAC pain, 8 | WOMAC fx, 8 | Timed walk (s), 8 | – |
| Rapp et al. [ | 60 (8) | – (–) | 39 (56) | K | A | N | Str | UC | – | VAS (0–10), 2 | – | Strength, 2 | – |
| Rathi et al. [ | 54 (7) | – (–) | 20 (–) | K | I | N | Ae | MEx | – | NRS, 0.5 | WOMAC fx (0–28), 1.5 | Strength, 0.5 | – |
| Rogers et al. [ | 71 (11) | 33 (7) | 20 (80) | K | UClr | N | Fl/Sk | Str | – | WOMAC pain (0–20), 2 | WOMAC fx (0–68), 1.5 | Timed up and go test (s), 2 | – |
| Rogers et al. [ | 70 (9) | 29 (–) | 33 (61) | K | A | N | Fl/Sk | MEx | Str | WOMAC pain (0–20), 2 | WOMAC fx (0–68), 2 | Timed up and go (s), 2 | – |
| Rogind et al. [ | 71 (7) | 27 (4) | 25 (84) | K | A, I | N | MEx | UC | – | VAS at rest (0–10), 3 | Algofunctional index, 3 | 20-m walk speed (m/s), 3 | – |
| Rooij et al. [ | 64 (–) | 36 (–) | 126 (75) | K | A | N | MEx | UC | – | NRS (0–10), 2.5 | WOMAC fx (0–68), 2.5 | 6MWT (m), 2.5 | – |
| Rosedale et al. [ | 65 (10) | 31 (7) | 158 (56) | K | I | Y | MEx | UC | – | KOOS pain (0–100), 3 | KOOS fx (0–100), 3 | – | KOOS QoL (0–100), 3 |
| Salacinski et al. [ | 58 (10) | 24 (–) | 37 (73) | K | I | N | Ae | UC | – | VAS at rest (0–100), 3 | WOMAC fx (0–100), 3 | Walking speed (m/s), 3 | KOOS–QoL (0–100), 3 |
| Salli et al. [ | 57 (7) | 32 (–) | 75 (77) | K | A, I | N | Str | UC | – | VAS at rest, 2 | WOMAC fx, 2 | Strength (180o/s peak torque), 2 | SF-36 mental health, 2 |
| Samut et al. [ | 60 (7) | 32 (–) | 42 (100) | K | A | N | Ae | Str | – | VAS (0–10), 1.5 | WOMAC (total) (0–96), 1.5 | 6MWT (m), 1.5 | – |
| Sayers et al. [ | 67 (7) | 31 (7) | 45 (56) | K | A | N | Fl/Sk | Str | – | WOMAC pain (0–20), 3 | WOMAC fx (0–68), 3 | Walking speed (s), 3 | – |
| Schilke et al. [ | 66 (–) | – (–) | 23 (74) | K | UClr | N | Str | UC | – | Osteoarthritis screening index pain, 2 | Arthritis Impact Measurement Scales activity, 2 | Strength, 2 | – |
| Sekir and Gur [ | 60 (9) | – (–) | 22 (73) | K | A | N | Fl/Sk | UC | – | VAS (0–100) after inactivity, 1.5 | NRS subjective functional rating (0–10), 1.5 | Timed walk (s), 1.5 | – |
| Simão et al. [ | 72 (6) | 28 (–) | 35 (80) | K | A, I | N | Str | UC | – | WOMAC pain (0–500), 3 | WOMAC fx (0–1700), 3 | 6MWT (m), 3 | – |
| Singh et al. [ | 57 (6) | 28 (3) | 200 (69) | K | UClr | N | Ae | MEx | – | VAS, 2 | WOMAC fx, 2 | Strength (isotonic), 2 | – |
| Skoffer et al. [ | 70 (–) | 31 (–) | 59 (61) | K | I | Y | Str | UC | – | KOOS pain (0–100), 1 | KOOS ADL (0–100), 1 | 6MWT (m), 1 | KOOS QoL (0–100), 1 |
| Sung-Bum et al. [ | 65 (3) | – (–) | 14 (100) | K | A, I | N | Fl/Sk | UC | – | VAS, 2-month | – | Strength (isokinetic), 2 | – |
| Swank et al. [ | 63 (7) | 34 (–) | 71 (65) | K | UClr | Y | MEx | UC | – | VAS (after walk test) (1–10), 1.5, outlier | – | 6MWT (m), 1.5 | – |
| Takacs et al. [ | 67 (–) | 29 (–) | 40 (80) | K | I | N | Fl/Sk | UC | – | NRS (0–10), 2.5 | WOMAC fx (0–68), 2.5 | Composite peak lower limb strength, 2.5 | – |
| Teirlinck et al. [ | 66 (–) | 28 (–) | 203 (59) | H | A | N | MEx | UC | – | NRS (0–10), 1.5 | HOOS fx (0–100), 1.5 | Timed up and go (s), 12 | EQ-5D, 1.5 |
| Teixeira et al. [ | 65 (9) | 30 (6) | 159 (65) | K | A, I | N | Fl/Sk | MEx | – | – | WOMAC fx—single item, 1.5 | – | – |
| Kuptniratsaikul et al. [ | 68 (6) | – (–) | 392 (78) | K | I | N | Str | UC | – | Pain score, 2 | Functional incapacity score (0–20), 2 | 6MWT (m), 2 | – |
| Thorstensson et al. [ | 56 (6) | 30 (–) | 61 (51) | K | I | N | MEx | UC | – | KOOS pain (0–100), 1.5 | KOOS (ADL) (0–100), 1.5 | One leg semi squatting, 1.5 | SF-36 mental health, 1.5 |
| Topp et al. [ | 63 (11) | – (–) | 102 (73) | K | A | N | Str | UC | – | WOMAC pain (0–20), 4 | WOMAC fx (0–68), 4 | Up stairs (s), 4 | – |
| Topp et al. [ | 64 (7) | 32 (6) | 54 (69) | K | UClr | Y | MEx | UC | – | VAS (0–10) at 6MWT, 1 | – | 6MWT (m), 1 | – |
| Tsauo et al. [ | 62 (9) | 27 (5) | 54 (87) | K | A, I | N | Fl/Sk | MEx | – | WOMAC pain (0–500), 2 | WOMAC fx (0–1700), 2 | 60-m walking (s), 2 | – |
| Vaittianadane et al. [ | – (–) | – (–) | 60 (–) | K | UClr | N | Fl/Sk | MEx | – | – | WOMAC (total), 1.5 | Timed up and go (s), 1.5 | – |
| Van Baar et al. [ | 68 (9) | – (–) | 201 (78) | K, H | A | N | MEx | UC | – | VAS past week (0–100), 3 | Influence of rheumatic disease on general health and lifestyle disability (−28–7), insufficient data | Muscle strength (knee), 3 | – |
| Wallis et al. [ | 68 (–) | 34 (–) | 46 (44) | K | I | N | Ae | UC | – | NRS (0–10), 3 | WOMAC ADL (0–68), 3 | 40-m walk test (m/s), 3 | EQ-5D (0–1), 3 |
| Wang et al. [ | 66 (12) | – (–) | 38 (84) | K, H | UClr | N | MEx | UC | – | VAS (0–100), 1.5 | Multidimensional health assessment questionnaire, 1.5 | Strength knee extension, 1.5 | – |
| Wang et al. [ | 68 (6) | 26 (2) | 78 (86) | K | UClr | N | MEx | UC | – | KOOS pain (0–100), 1.5 | KOOS ADL (0–100), 1.5 | 6MWT (m), 1.5 | KOOS QoL (0–100), 1.5 |
| Weidenhielm et al. [ | 64 (5) | – (–) | 39 (51) | K | UClr | Y | MEx | UC | – | Pain 10-grade scale (walking), 3 | – | Max walking speed (m/min), 3 | – |
| Weng et al. [ | 64 (8) | – (–) | 132 (80) | K | A | N | Fl/Sk | MEx | – | VAS after walking (0–10), 2 | Lequesne index (1–26), 2 | Peak torque, 2 | – |
| Wortley et al. [ | 69 (6) | 32 (6) | 31 (71) | K | A, I | N | MB | Str | – | WOMAC pain, 2.5 | WOMAC fx, 2.5 | 6MWT (m), 2.5 | – |
A American College of Rheumatology, ADL activity of daily living, Ae Aerobic, AQoL Assessment of Quality of Life, BMI body mass index, fem female, Fl/Sk flexibility and skills, fx function, H hip, HOOS Hip disability and Osteoarthritis Outcome Score, I imaging criteria, ICOAP Measure of Intermittent and Constant Osteoarthritis Pain, Jt joint, K knee, KOOS Knee injury and Osteoarthritis Outcome Score, m meter, MB mind–body, MCS mental composite score, MEx mixed exercise, n sample size, N no, NHP Nottingham Health Profile questionnaire, NRS Numeric rating score, QoL quality of life, s seconds, SD standard deviation, SF-36 36-item short form survey, Str strengthening; UC usual care, UClr unclear, VAS visual analogue scale, WOMAC Western Ontario & McMaster Universities Osteoarthritic Index, Y yes, 6MWT 6-minute walk test
aTrials with multiple reporting available
bTwo sets of comparison were obtained
Characteristics of studies by outcomes
| Pain | Function | Performance | QoL | |
|---|---|---|---|---|
| No. of comparisons | 97 | 97 | 105 | 42 |
| Versus usual care | 70 | 67 | 74 | 34 |
| Versus another exercise | 27 | 30 | 31 | 8 |
| No. of trials (no. participants) | 89 (7184) | 87 (7153) | 95 (6760) | 40 (3190) |
| Knee | 75 (5607) | 73 (5733) | 78 (5156) | 30 (2073) |
| Hip | 8 (703) | 9 (754) | 10 (905) | 7 (585) |
| Both | 6 (874) | 5 (666) | 7 (699) | 3 (532) |
| Age, median (IQR), years | 64.9 (62.0–68.7) | 64.9 (62.0–69.1) | 65.1 (62.4–69.8) | 65.3 (62.0–69.7) |
| BMI, median (IQR), kg/m2 | 29.0 (27.1–31.5) | 29.4 (27.2–31.5) | 29.0 (27.1–31.5) | 29.5 (27.1–31.5) |
| Female, median (IQR), % | 73.0 (61.0–80.7) | 73.4 (62.8–81.0) | 73.0 (64.1–81.0) | 73.7 (61.0–93.2) |
| Study design | ||||
| 2 arms | 86 | 83 | 91 | 39 |
| 3 arms | 3 | 4 | 4 | 1 |
Data presented for each outcome excludes outliers and un-extractable data
BMI body mass index, IQR interquartile range, QoL quality of life
Fig. 2Network of direct comparisons formed by included studies. The size of nodes and lines connecting the nodes are proportionate to the number of participants and the number of trials, respectively. Data represent number of trials (number of participants). Flex/Skills flexibility and skills or neuromuscular training
Fig. 3Effect size of different exercise types versus different comparators presented in standardised means difference (95% credibility interval). Flex/Skills flexibility and skills exercises, n number analysed
Subgroup analysis by joint and recruitment
| Effect size (95% credibility interval) | ||||
|---|---|---|---|---|
| Joint | Recruitment | |||
| Knee OA | Hip OA | Not awaiting TJR | Awaiting TJR | |
| Pain | 75 trials ( | 8 trials ( | 75 trials ( | 14 trials ( |
| Aerobic | 1.16 (0.70, 1.61) | 1.15 (0.73, 1.59) | ||
| Mind–body | 1.30 (0.73, 1.86) | 1.13 (0.65, 1.61) | ||
| Strength | 0.76 (0.50, 1.02) | 0.53 (− 0.74, 1.80) | 0.81 (0.54, 1.08) | 0.46 (− 0.28, 1.18) |
| Flex/skills | 0.69 (0.31, 1.07) | 0.70 (0.33, 1.07) | 0.58 (− 1.20, 2.35) | |
| Mixed | 0.57 (0.29, 0.85) | 0.12 (− 0.36, 0.62) | 0.52 (0.29, 0.76) | 0.25 (− 0.42, 0.93) |
| Heterogeneity | 0.67 (0.54, 0.82) | 0.54 (0.22, 1.20) | 0.62 (0.51, 0.77) | 0.81 (0.47, 1.37) |
| Function | 73 trials ( | 9 trials ( | 76 trials ( | 11 trials ( |
| Aerobic | 0.64 (0.11, 1.17) | 0.63 (0.19, 1.07) | 0.12 (− 3.11, 3.38) | |
| Mind–body | 0.93 (0.27, 1.59) | 0.83 (0.35, 1.30) | ||
| Strength | 0.78 (0.47, 1.09) | 0.69 (− 0.17, 1.54) | 0.72 (0.46, 0.99) | 0.90 (− 0.58, 2.36) |
| Flex/skills | 0.74 (0.29, 1.19) | 0.68 (0.33, 1.03) | ||
| Mixed | 0.55 (0.21, 0.89) | 0.15 (− 0.17, 0.46) | 0.46 (0.23, 0.69) | 0.09 (− 1.53, 1.71) |
| Heterogeneity | 0.81 (0.67, 0.98) | 0.32 (0.05, 0.75) | 0.61 (0.50, 0.74) | 1.69 (1.00, 2.97) |
| Performance | 78 trials ( | 10 trials ( | 81 trials ( | 14 trials ( |
| Aerobic | 1.12 (0.61, 1.62) | 0.81 (0.23, 1.42) | 1.05 (0.62, 1.49) | |
| Mind–body | 0.68 (0.03, 1.31) | 0.53 (0.01, 1.07) | ||
| Strength | 0.60 (0.33, 0.87) | 0.29 (− 0.13, 0.75) | 0.51 (0.25, 0.77) | 0.78 (0.13, 1.43) |
| Flex/skills | 0.76 (0.38, 1.14) | 0.66 (0.30, 1.03) | 0.90 (− 0.72, 2.53) | |
| Mixed | 0.60 (0.31, 0.90) | 0.17 (− 0.04, 0.41) | 0.50 (0.27, 0.74) | 0.35 (− 0.26, 0.97) |
| Heterogeneity | 0.72 (0.58, 0.87) | 0.18 (0.01, 0.51) | 0.65 (0.53, 0.79) | 0.71 (0.41, 1.21) |
| Quality of life | 30 trials ( | 7 trials ( | 30 trials ( | 10 trials ( |
| Aerobic | 0.39 (− 0.13, 0.93) | 0.38 (− 0.02, 0.79) | ||
| Mind–body | 0.37 (− 0.11, 0.86) | 0.25 (− 0.05, 0.55) | ||
| Strength | 0.27 (0.00, 0.54) | 0.30 (− 0.37, 0.97) | 0.36 (0.12, 0.62) | 0.13 (− 0.40, 0.66) |
| Flex/skills | 0.35 (− 0.10, 0.80) | 0.41 (0.07, 0.74) | ||
| Mixed | 0.25 (− 0.02, 0.52) | 0.06 (− 0.21, 0.36) | 0.22 (0.07, 0.38) | 0.10 (− 0.56, 0.79) |
| Heterogeneity | 0.35 (0.19, 0.54) | 0.19 (0.00, 0.70) | 0.19 (0.03, 0.36) | 0.53 (0.19, 1.09) |
Heterogeneity presented as between-studies standard deviation and 95% credibility interval (CrI)
Flex/Skills flexibility/skills exercise, n number of participants analysed, OA osteoarthritis, TJR total joint replacement
| The effect of exercise in knee and hip osteoarthritis depends on type of exercise and outcome of interest. |
| Aerobic and mind–body exercises appear to be the two most effective exercise therapies for pain and function, whereas strengthening and flexibility exercises appear to be good for moderate improvement of multiple outcomes. |
| Mixed exercise is the least effective exercise. However, it may be used for patients who do not respond to other types of exercise therapy because it is still better than no exercise control for all four patient-centred outcomes. |